KRRO — Korro Bio, Inc.
NASDAQ · Healthcare · Biotechnology
$12.24
-$0.25 (-2.00%)
Korro Bio, Inc. (KRRO) is a biotechnology company listed on NASDAQ. It is led by Ram Aiyar MBA, Ph.D., based in 60 First Street, Cambridge, MA, United States, 02141, with about 49 employees. Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Latest reported KRRO revenue for 2025-09-30 was $1.1M. Net income was -$67.2M. Revenue was down 25.3% from 2025-06-30 to 2025-09-30. KRRO currently screens at market cap $159.8M.
Use this KRRO page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the KRRO quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the KRRO SEC filings page. Lician reads the product cache first so this HTML stays unique to Korro Bio, Inc. even when a live quote feed is slow.
About Korro Bio, Inc.
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
KRRO Key Statistics
Market Cap
$159.80M
Volume
79,708
Previous Close
$13.07
Day Range
$13.14 – $13.90
EPS
-$9.37
Revenue
$2.27M
Net Income
-$83.58M
Gross Profit
$0.00
Free Cash Flow
$0.00
Profit Margin
-3680.4%
Employees
49
KRRO Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $2.27M | $0.00 | $0.00 | $14.07M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$83.58M | -$81.17M | -$58.03M | -$84.69M |
| EPS (Diluted) | -$9.37 | -$53.08 | -$227.42 | $0.00 |
Total Assets
$226.24M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$55.64M
Operating Cash Flow
-$60.07M
Free Cash Flow
$0.00
Korro Bio, Inc. Company Information
- CEO, President, Interim CFO, Principal Financial Officer & Director
- Ram Aiyar MBA, Ph.D.
- Headquarters
- 60 First Street, Cambridge, MA, United States, 02141
- Website
- www.korrobio.com
- Phone
- 617 468 1999
- IPO / Founded
- 2023-11-06
- Sector
- Healthcare
- Industry
- Biotechnology